Radioiodine Treatment with 30 mCi after Recombinant Human Thyrotropin Stimulation in Thyroid Cancer: Effectiveness for Postsurgical Remnants Ablation and Possible Role of Iodine Content in<scp>l</scp>-Thyroxine in the Outcome of Ablation

Bari, Lorenzo Di; Boni, Giuseppe; Meucci, Giuseppe; Simi, U; Lapi, Paola; Orsini, Paola; Pasquini, Cristina; Piazza, Francesca; Caciagli, Marco; Mariani, Giuliano

doi:10.1210/jc.2003-030298

Cited by 135 publications

(84 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some patients, unable to tolerate hypothyroidism or unable to generate an elevated TSH, have undergone successful remnant ablation with rhTSH (159,160). Successful remnant ablation with 30 mCi 131 I was equivalent after thyroxine withdrawal compared to rhTSH stimulation when the thyroxine therapy was stopped 1 day prior to the rhTSH injections and restarted the day after 131 I therapy (161). rhTSH is not approved in the United States for this indication, but it is approved in Europe.…”

Section: Can Recombinant Human Thyrotropin (Thyrogen™) Be Used In Liementioning

confidence: 99%

Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Taskforce

Cooper

Doherty

Haugen

et al. 2006

Thyroid

1,921

938

View full text Add to dashboard Cite

Section: Can Recombinant Human Thyrotropin (Thyrogen™) Be Used In Liementioning

confidence: 99%

Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Taskforce

Cooper

Doherty

Haugen

et al. 2006

Thyroid

1,921

938

View full text Add to dashboard Cite

“…Qualidade de vida relacionada à voz e à deglutição, a curto prazo, em pacientes submetidos à radioiodoterapia por carcinoma diferenciado de tireoide José Ribamar do Nascimento Junior (1) , Elisabete Carrara-de Angelis (2) , Eduardo Nóbrega Pereira Lima (3)…”

Section: Short Term Quality Of Life Related To Voice and Swallowing Iunclassified

Qualidade de vida relacionada à voz e à deglutição, a curto prazo, em pacientes submetidos à radioiodoterapia por carcinoma diferenciado de tireoide

Nascimento¹,

Angelis

Lima

2015

Rev. CEFAC

View full text Add to dashboard Cite

Qualidade de vida relacionada à voz e à deglutição, a curto prazo, em pacientes submetidos à radioiodoterapia por carcinoma diferenciado de tireoide José Ribamar do Nascimento Junior (1) , Elisabete Carrara-de Angelis (2) , Eduardo Nóbrega Pereira Lima (3)Instituto de Gerenciamento em deglutição -IGD São Paulo, SP, Brasil.Departamento de Fonoaudiologia do Hospital AC Camargo São Paulo, SP, Brasil.Departamento de Medicina Nuclear do Hospital AC Camargo, São Paulo, SP, Brasil. Conflict of interest: non-existentThe main structures at risk during thyroid surgery are the recurrent laryngeal nerves and parathyroid glands. The removal of the parathyroid glands can lead to hypoparathyroidism and consequent hypocalcemia 1,3 . Lesion to the inferior recurrent laryngeal nerve can result in vocal fold paralysis, which may cause permanent hoarseness. If the lesion is bilateral, aphonia and dyspnea are results of changes in the vocal folds 4 .In thyroid surgery, its comorbidities is postsurgical therapy with ¹³¹I leading to prolonged survival, and patients may present vocal alterations, dysphagia, sialadenitis, taste changes and xerostomia 5 .Sialadenitis is a possible side effect seen in treatment with high doses of ¹³¹I and correlates with the amount administered and physiological uptake, usually bilateral, in the region of the parotid or submandibular glands, which occurs within 48 INTRODUTCIONDiseases of the thyroid gland are common, affecting approximately 11% of the general population, with a predominance of female involvement over male in a ratio of 4:1 1 . The initial treatment of well-differentiated thyroid carcinoma consists in most cases of total or near total thyroidectomy with subsequent remnant ablation with iodine radioisotope (¹³¹I) followed by L-thyroxine (L-T4) suppression 2 . ABSTRACTPurpose: to analyze the quality of life related to voice and swallowing before and after radioiodine therapy in the short term. Methods: thiroidectomized individuals indicated RAI underwent two questionnaires on quality of life related to voice and swallowing before and three months after radioiodine therapy. Results: 32 patients, 84 % female and 16% male, were studied with a mean age of 46 years. The histological type was the classic papillary carcinoma (56%). The results indicated a tendency for better quality of life with respect to voice three months after radioiodine therapy. The protocol for quality of life related to swallowing also indicated better quality of life in the second assessment. A larger with minimal limitation on the quality of life questionnaire in swallowing was observed. Conclusion: quality of life and voice and swallowing symptoms in the short term after radioiodine therapy is better compared to pretreatment. It is necessary to investigate other aspects such as metabolic, surgical and individual to define the real impact of radioiodine therapy on quality of life.

show abstract

“…For the studies using 1.11 GBq (30 mCi) 131 I, the results are more differentiated: whereas the studies by Barbaro et al [6,7] did not show a significant difference in the rates of successful ablation between patients prepared with rhTSH and LT 4 withdrawal, Pacini et al [5] did find a considerable difference. Some speculation is possible about the reason for the difference found by Pacini et al; the most likely explanation is that the administration of the ablative 131 I activity on the second day after the last administration of rhTSH is too late.…”

mentioning

confidence: 92%

“…Its effectiveness in patient preparation before 131 I ablation has been shown in multiple prospective studies [1][2][3][4][5][6][7].…”

mentioning

confidence: 99%

“…Consequently it is conceivable that the lower the ablative 131 I activity used, the more important the reduction of stable iodine becomes. The studies by Barbaro et al [6,7], who performed ablation under rhTSH stimulation with an activity of only 1.1 GBq after patient preparation with a stringent diet as well as a socalled mini-withdrawal (i.e. the discontinuation of LT 4 for 4 days before 131 I administration as it is a source of stable iodine), seem to prove that it is possible to effectively ablate patients using only 1.11 GBq when paying attention to the reduction of the whole-body iodine pool; the ablation success rates in the studies by Barbaro et al were comparable with those in studies which used a higher ablative 131 I activity.…”

mentioning

confidence: 99%

See 1 more Smart Citation

ALARA in rhTSH-stimulated post-surgical thyroid remnant ablation: what is the lowest reasonably achievable activity?

Bari

Verburg

Luster

et al. 2010

Eur J Nucl Med Mol Imaging

Self Cite

View full text Add to dashboard Cite

Radioiodine Treatment with 30 mCi after Recombinant Human Thyrotropin Stimulation in Thyroid Cancer: Effectiveness for Postsurgical Remnants Ablation and Possible Role of Iodine Content inl-Thyroxine in the Outcome of Ablation

Cited by 135 publications

References 26 publications

Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Taskforce

Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Taskforce

Qualidade de vida relacionada à voz e à deglutição, a curto prazo, em pacientes submetidos à radioiodoterapia por carcinoma diferenciado de tireoide

ALARA in rhTSH-stimulated post-surgical thyroid remnant ablation: what is the lowest reasonably achievable activity?

Contact Info

Product

Resources

About